Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
271. |
ECCT/21/06/14 | CoVPN 3008 Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Kisumu Clinical Research Site (Kisumu county) |
13-12-2021 |
View |
272. |
ECCT/21/06/13 | CARES A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) 3. Aga khan University Hospital (Nairobi City county) |
18-11-2021 |
View |
273. |
ECCT/21/07/02 | TALIOS A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
01-11-2021 |
View |
274. |
ECCT/22/10/03 | ISSC A randomized, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics, and efficacy of escalating doses of oral ivermectin in scabies infected children weighing 5 to less than 15 kilograms in Kenya |
Principal Investigator(s) 1. Eunice Akinyi Ouma Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital |
14-02-2024 |
View |
275. |
ECCT/21/06/10 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. Kishorchandra Narsinh Mandaliya Site(s) in Kenya 1. Kenya Medical Research Institute (Kisumu county) 2. KEMRI/Walter Reed Project Research Center (Kericho county) 3. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county) 4. KEMRI CMR (Kisumu county) 5. Kenya Medical Research Institute (Nairobi City county) 6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 7. Moi University Clinical Research Centre (Uasin Gishu county) 8. Aga Khan University Hospital (Nairobi City county) 9. KEMRI CCR-Butere County Hospital Site (Kakamega county) 10. Ganjoni Clinic (Mombasa county) |
16-08-2021 |
View |
276. |
ECCT/21/07/03 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Prof Jessie N Githanga 2. Fredrick Sirwa Chite 3. Bernhards Ragama Ogutu 4. Videlis N Nduba Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. Strathmore University Medical Centre (Nairobi City county) |
08-11-2021 |
View |
277. |
ECCT/21/06/15 | Therapeutic Efficacy Study Efficacy of Artemether Lumefantrine (AL) and Dihydroartemisinin-Piperaquine (DHP) for the treatment of uncomplicated Plasmodium falciparum malaria in Siaya and Bungoma counties, Kenya. |
Principal Investigator(s) 1. Dr. Sarah-Blythe Ballard 2. Dr. Willis Akhwale 3. Dr. Grace Ikahu 4. Dr. George Githuka 5. Dr. Dickson Mtungu Mwakangalu 6. Dr. Elvis Omondi Oyugi 7. Hellen Gatakaa 8. Regina Jepkosgei Kandie 9. Dr. Fredrick Ouma Odhiambo Site(s) in Kenya 1. Mahonge Health Center (Bung\'oma county) 2. Kaluo Health Center (Siaya county) |
11-08-2021 |
View |
278. |
ECCT/21/06/08 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older |
Principal Investigator(s) 1. Saleh Mansoor Site(s) in Kenya 1. Aga Kahn University Nairobi (Nairobi City county) 2. Kenya Medical Research Institute (Kisumu county) 3. KEMRI/Walter Reed Project Research Center (Kericho county) 4. Ganjoni Clinic (Mombasa county) 5. KEMRI/CCR Partners in Health R&D (PHRD (Kiambu county) 6. KEMRI/CCR Partners in Health R&D (PHRD (Kiambu county) 7. Kenya Medical Research Institute (Nairobi City county) 8. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 9. Moi University Clinical Research Centre (Uasin Gishu county) 10. KEMRI CCR-Butere County Hospital Site (Kakamega county) |
16-08-2021 |
View |
279. |
ECCT/21/06/06 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older |
Principal Investigator(s) 1. Janet Oyieko Site(s) in Kenya 1. KEMRI CCR-Butere County Hospital Site (Kakamega county) 2. Kenya Medical Research Institute (Kisumu county) 3. KEMRI/Walter Reed Project Research Center (Kericho county) 4. Ganjoni Clinic (Mombasa county) 5. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county) 6. Kenya Medical Research Institute (Nairobi City county) 7. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 8. Moi University Clinical Research Centre (Uasin Gishu county) 9. Aga Khan University Hospital (Nairobi City county) 10. Kenya Medical Research Institute (Kisumu county) 11. KEMRI/Walter Reed Project Research Center (Kericho county) 12. Ganjoni Clinic (Mombasa county) 13. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county) 14. Kenya Medical Research Institute (Nairobi City county) 15. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 16. Moi University Clinical Research Centre (Uasin Gishu county) 17. Aga Khan University Hospital (Nairobi City county) 18. Kenya Medical Research Institute (Kisumu county) 19. KEMRI/Walter Reed Project Research Center (Kericho county) 20. Ganjoni Clinic (Mombasa county) 21. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county) 22. Kenya Medical Research Institute (Nairobi City county) 23. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 24. Moi University Clinical Research Centre (Uasin Gishu county) 25. Aga Khan University Hospital (Nairobi City county) 26. Kenya Medical Research Institute (Kisumu county) 27. KEMRI/Walter Reed Project Research Center (Kericho county) 28. Ganjoni Clinic (Mombasa county) 29. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county) 30. Kenya Medical Research Institute (Nairobi City county) 31. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 32. Moi University Clinical Research Centre (Uasin Gishu county) 33. Aga Khan University Hospital (Nairobi City county) 34. Kenya Medical Research Institute (Kisumu county) 35. KEMRI/Walter Reed Project Research Center (Kericho county) 36. Ganjoni Clinic (Mombasa county) 37. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county) 38. Kenya Medical Research Institute (Nairobi City county) 39. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 40. Moi University Clinical Research Centre (Uasin Gishu county) 41. Aga Khan University Hospital (Nairobi City county) |
16-08-2021 |
View |
280. |
ECCT/21/06/05 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR-PHRD THIKA PROJECT |
02-08-2021 |
View |